BACKGROUND: Short-term (≤ 6 months) dual antiplatelet therapy (DAPT) and DAPT de-
escalation become attractive for patients with acute coronary syndrome. METHODS: A …

Aims: Several scoring systems, including the ABCD-GENE and HHD-GENE scores
incorporating clinical and genetic factors, have been developed to identify patients likely to …

Introduction Dual antiplatelet therapy (DAPT) including prasugrel or ticagrelor is
recommended in patients with acute coronary syndromes (ACS) treated with coronary …

Background Although there is a growing body of evidence that CYP2C19 genotyping can be
beneficial when considering treatment with clopidogrel after percutaneous coronary …

Introduction Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is a
cornerstone in the treatment of patients with acute coronary syndrome (ACS) undergoing …

Loss‐of‐function (LoF) alleles of cytochrome P450 2C19 (CYP2C19), which are prevalent in
East Asians, are linked to high platelet reactivity (HPR) phenotype and poor prognosis. We …

Background and aims Elderly patients with acute coronary syndrome (ACS) tend to choose
clopidogrel over potent P2Y12 receptor inhibitor such as ticagrelor after percutaneous …

Objectives To investigate outcomes with selective, clopidogrel-based therapies versus
conventional treatment in patients undergoing percutaneous coronary intervention (PCI) …

Dual antiplatelet therapy (DAPT) is the gold standard for the antithrombotic management of
patients with an acute coronary syndrome (ACS) or undergoing percutaneous coronary …

Background: Uncertainty exists about the link between omega-3 fatty acid, omega-6 fatty
acid, and total polyunsaturated fatty acid (PUFA) intake and mortality in atherosclerotic …